Pancreatic Cancer Research

ResearcherUniversidad de AlcaláActive in the last 2 years

Alfredo Carrato

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7749-8140; OpenAlex author ID A5073682977, A5129547976, A5158632256. Sources: ClinicalTrials.gov.

Their work

Papers
67 (first author 2, last author 12)
Trials
1
Grants
0
Labs led
2
Collaborators
274
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 5 papers, 1 trial · 2016: 3 papers · 2017: 7 papers · 2018: 4 papers · 2019: 5 papers · 2020: 9 papers · 2021: 8 papers · 2022: 6 papers · 2023: 2 papers · 2024: 5 papers · 2025: 6 papers · 2026: 4 papers

Papers 50 of 67

  1. Publisher Correction: Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-026-69055-2↗
  2. A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study. Co-author DOI 10.1158/1055-9965.epi-25-1601↗
  3. Stromal-associated extracellular vesicles snRNAs and piRNAs as non-invasive diagnostic and prognostic biomarkers in colon and pancreatic cancer Co-author DOI 10.21203/rs.3.rs-10396814/v1↗
  4. Stroma-associated extracellular vesicles snRNAs and piRNAs as non-invasive diagnostic and prognostic biomarkers in colon and pancreatic cancer Co-author DOI 10.21203/rs.3.rs-8948517/v1↗
  5. Low type-2 immune effectors modulate atopic diseases' protective role in pancreatic cancer risk. Co-author DOI 10.1002/ijc.35397↗
  6. Combined analysis of a serum mRNA/miRNA marker signature and CA 19-9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adeno… Co-author DOI 10.1002/ueg2.12676↗
  7. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Co-author DOI 10.1016/j.ejso.2024.109544↗
  8. Real-world management and outcome of patients with pancreatic adenocarcinoma. Results of the Spanish RETUD gastrointestinal registry. Co-author DOI 10.1016/j.esmorw.2025.100116↗
  9. Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-025-65811-y↗
  10. Drug Repurposing in Pancreatic Cancer: A Multi-Stakeholder Perspective to Improve Treatment Options for Pancreatic Cancer Patients. Co-author DOI 10.2147/cmar.s483151↗
  11. The Spanish Familial Pancreatic Cancer Registry (PANGENFAM): a decade follow-up of individuals at high-risk for pancreatic cancer. Last author DOI 10.1007/s10689-024-00388-x↗
  12. The best linear unbiased prediction (BLUP) method as a tool to estimate the lifetime risk of pancreatic ductal adenocarcinoma in high-risk individuals with no … Co-author DOI 10.1007/s10689-024-00397-w↗
  13. Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer. Co-author DOI 10.1056/evidoa2300144↗
  14. HLA-A*02:01allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaustive analysis of theHLAvariation in PDAC Co-author DOI 10.1101/2024.08.29.24312704↗
  15. The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells. Co-author DOI 10.1136/gutjnl-2023-330995↗
  16. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325564↗
  17. Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue. Co-author DOI 10.3791/65229↗
  18. Clinical nutrition as part of the treatment pathway of pancreatic cancer patients: an expert consensus. Co-author DOI 10.1007/s12094-021-02674-x↗
  19. Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis. Co-author DOI 10.1016/j.ebiom.2021.103797↗
  20. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  21. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Co-author DOI 10.1053/j.gastro.2021.10.014↗
  22. A faecal microbiota signature with high specificity for pancreatic cancer. Co-author DOI 10.1136/gutjnl-2021-324755↗
  23. Detection of Early-Stage Pancreatic Ductal Adenocarcinoma From Blood Samples: Results of a Multiplex Biomarker Signature Validation Study. Co-author DOI 10.14309/ctg.0000000000000468↗
  24. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.33464↗
  25. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  26. Gallbladder disease and pancreatic cancer risk: a multicentric case-control European study. Co-author DOI 10.1097/cej.0000000000000588↗
  27. Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. Co-author DOI 10.1136/gutjnl-2019-319990↗
  28. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Co-author DOI 10.1186/s13073-020-00816-4↗
  29. Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer. Co-author DOI 10.2217/fon-2020-0749↗
  30. Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer O… Last author DOI 10.3390/cancers13071612↗
  31. Correction: Earl et al. Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS N… Last author DOI 10.3390/cancers13153687↗
  32. A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants. Last author DOI 10.1016/j.ebiom.2020.102675↗
  33. Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated … Co-author DOI 10.1016/j.ejca.2020.07.035↗
  34. ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity. Co-author DOI 10.1038/s41467-020-16395-2↗
  35. First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observa… Co-author DOI 10.1136/esmoopen-2019-000587↗
  36. Bratislava Statement: consensus recommendations for improving pancreatic cancer care. Co-author DOI 10.1136/esmoopen-2020-001051↗
  37. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAP… Co-author DOI 10.1136/gutjnl-2019-319352↗
  38. Correction: Management of patients with increased risk for familial pancreatic cancer: updated recommendations for the international cancer of the pancreas scr… Co-author DOI 10.1136/gutjnl-2019-319352corr1↗
  39. Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Dose-Response Relationships. Co-author DOI 10.1158/1055-9965.epi-19-1027↗
  40. Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance? Co-author DOI 10.3390/ijms21114091↗
  41. Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological case-control approaches. Co-author DOI 10.1002/ijc.31866↗
  42. Screening of Individuals at High Risk for Pancreatic Cancer Last author DOI 10.1016/j.cgh.2019.03.023↗
  43. Management and supportive treatment of frail patients with metastatic pancreatic cancer. First author DOI 10.1016/j.jgo.2018.06.005↗
  44. Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance. Co-author DOI 10.1038/s41388-019-0803-9↗
  45. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Co-author DOI 10.1136/gutjnl-2017-314828↗
  46. Management of hyperbilirubinaemia in pancreatic cancer patients. First author DOI 10.1016/j.ejca.2018.01.078↗
  47. Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives. Co-author DOI 10.1093/ije/dyx269↗
  48. Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker. Co-author DOI 10.18632/oncotarget.26034↗
  49. From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. Last author DOI 10.7150/jca.23716↗
  50. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Last author DOI 10.1007/s12094-016-1594-x↗

Trials 1

  1. Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma Study chair NCT02504333↗

Closest collaborators

The 25 strongest of 274 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Julie Earl · 21 shared papers, 2015–2025 · strength 2.21
  2. Núria Malats · 21 shared papers, 2011–2025 · strength 1.79
  3. Thomas Mathias Gress · 14 shared papers, 2016–2025 · strength 1.28
  4. Teresa Mercade Macarulla · 11 shared papers, 2015–2025 · strength 1.27
  5. Francisco X. Real · 15 shared papers, 2011–2025 · strength 1.12
  6. William Greenhalf · 12 shared papers, 2015–2025 · strength 0.96
  7. Rita Teresa Lawlor · 8 shared papers, 2017–2025 · strength 0.83
  8. Bruno Sáinz · 7 shared papers, 2019–2024 · strength 0.79
  9. Aldo Scarpa · 9 shared papers, 2017–2025 · strength 0.79
  10. Luis Muñoz‐Bellvís · 9 shared papers, 2017–2025 · strength 0.76
  11. J. Enrique Domínguez‐Muñoz · 9 shared papers, 2017–2025 · strength 0.76
  12. Jorg H. Kleeff · 9 shared papers, 2017–2025 · strength 0.76
  13. Tatjana Crnogorac‐Jurcevic · 9 shared papers, 2017–2025 · strength 0.76
  14. Carolina de la Pinta · 4 shared papers, 2023–2026 · strength 0.74
  15. Matthias J. Löhr · 9 shared papers, 2017–2025 · strength 0.74
  16. Eithne Costello · 10 shared papers, 2015–2024 · strength 0.70
  17. Linda Sharp · 8 shared papers, 2017–2024 · strength 0.58
  18. Bo Kong · 8 shared papers, 2017–2024 · strength 0.58
  19. Carmen Guillén‐Ponce · 9 shared papers, 2015–2024 · strength 0.57
  20. Esther Molina‐Montes · 8 shared papers, 2017–2022 · strength 0.56
  21. Eduardo Lobo · 5 shared papers, 2015–2024 · strength 0.55
  22. Paulina Gómez-Rubio · 8 shared papers, 2017–2022 · strength 0.54
  23. Christoph W. Michalski · 7 shared papers, 2017–2024 · strength 0.54
  24. Weimin Ye · 6 shared papers, 2018–2024 · strength 0.52
  25. Detlef Klaus Bartsch · 6 shared papers, 2016–2022 · strength 0.51

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.